Prokaryotes use an adaptive immune system called CRISPR-Cas to defend against phages and other mobile genetic elements. These systems acquire short pieces of DNA from their invaders as a genetic record of prior infections. They use these to produce CRISPR RNAs that are assembled with one or more Cas proteins into RNA-guided interference complexes that find and cleave a complementary target in foreign DNA or RNA. While most types of CRISPR-Cas systems target only one type of nucleic acid, Type III CRISPR systems have been reported to target both DNA and RNA. The identity of the true target nucleic acid of Type III systems thus remains unknown. A bacterial Type III-A system was reported to target transcriptionally active loci in vivo, leading to the hypothesis that the transcription bubble, at which DNA and RNA are both present, is the physiological target. Target recognition by the interference complex thus may involve simultaneous recognition of both DNA and RNA. In order to test this model, we propose to 1) trap a Type III-A (Csm) complex bound to a transcriptionally active target and use cryo-electron microscopy to determine the structure of the complex and 2) use protein-nucleic acid binding and nucleic acid cleavage assays to determine if RNA binding recruits the Type III-A (Csm) complex to the transcription bubble. This would lay the groundwork for repurposing these systems to detect transcriptionally active loci, and regulate gene expression in heterologous organisms.

Public Health Relevance

The discovery of the precise and programmable DNA targeting ability of the bacterial RNA-guided defense system, CRISPR-Cas, has led to their rapid development as tools for genome analysis. This study proposes to identify how a Type III CRISPR-Cas system identifies regions of the genome that are actively expressed, i.e. which affect the function of cells. The results may lead to a tool that could be used to detect differences in gene expression between cells or tissues in order to identify disease mechanisms and determine what may lead to an increased risk of diseases like cancer, heart disease, or diabetes.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Postdoctoral Individual National Research Service Award (F32)
Project #
1F32GM122334-01
Application #
9259287
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Maas, Stefan
Project Start
2017-04-01
Project End
2019-03-31
Budget Start
2017-04-01
Budget End
2018-03-31
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of California Berkeley
Department
Type
Organized Research Units
DUNS #
124726725
City
Berkeley
State
CA
Country
United States
Zip Code
94704